AS1842856
FOXO1 inhibitor / AS1842856 potent and selective FOXO1 inhibitor, IC50s=33 nM and >1 mM for FOXO3a and 4.1 Oral administration to diabetic db/db mice leads to a reduction of fasting plasma glucose levels.1 Suppresses autophagy, FSP27 expression and adipocyte differentiation.2 AS1842856 is a highly useful tool for probing the involvement of FOXO1 in cellular processes.3-5
Biochemicals & reagents
836620-48-5
1 Nagashima et al. (2010), Discovery of novel forkhead box O1 inhibitors for treating type 2 diabetes: improvement of fasting glycemia in diabetic db/dbmice; Mol. Pharmacol. 78 961 2 Liu et al. (2016), FoxO1 antagonist suppresses autophagy and lipid droplet growth in adipocytes; Cell Cycle 15 2033 3 Galley et al. (2019), Antagonism of Forkhead Box Subclass O Transcription Factors Elicits Loss of Soluble Guanylyl Cyclase Expression; Mol. Pharmacol. 95 629 4 Chen et al. (2024), SIRT1 silencing ameliorates malignancy of non-small cell lung cancer via activating FOXO1; Sci. Rep. 14 19948 5 Yang et al. (2023), Suppression of FOXO1 attenuates inflamm-aging and improves liver function during aging; Aging Cell 22 e13968
-20°C
TARGET: Transcription factor -- PATHWAY: Transcription; Autophagy; Glucose metabolism; Fatty acid metabolism -- RESEARCH AREA: Cell death; Stem cells; Cancer stem cells -- DISEASE AREA: Diabetes